`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`FRESENIUS KABI USA, LLC,
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`______________
`
`Case IPR2022-00657
`Patent 8,114,833
`______________
`
`DECLARATION OF LAURA T. MORAN IN SUPPORT OF PATENT
`OWNER’S MOTION FOR ADMISSION PRO HAC VICE OF LAURA T.
`MORAN UNDER 37 C.F.R. § 42.10(c)
`
`Novo Nordisk A/S Ex. 2001, P. 1
`Fresenius Kabi v. Novo Nordisk
`IPR2022-00657
`
`
`
`I, Laura T. Moran, declare as follows:
`
`1. I am a member in good standing of the New York State Bar (admitted
`
`2011), as well as the following Federal Courts: U.S. District Court for the Southern
`
`District of New York (admitted 2013), U.S. District Court for the Eastern District of
`
`New York (admitted 2020), and the U.S. Court of Appeals for the Federal Circuit
`
`(admitted 2014).
`
`2. I have never been suspended or disbarred from practice before any court
`
`or administrative body.
`
`3. I have never had an application for admission to practice before any
`
`court or administrative body denied.
`
`4. I have had no sanctions or contempt citations imposed against me by
`
`any court or administrative body.
`
`5. I have read and will comply with the Office Patent Trial Practice Guide
`
`and updates thereto and the Board’s Rules of Practice for Trials set forth in part 42
`
`of title 37 Code of Federal Regulations.
`
`6. I agree to be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et seq. and to disciplinary jurisdiction under 37 C.F.R.
`
`§ 11.19(a).
`
`7. Within the past three years, I have previously applied for and been
`
`granted permission to appear pro hac vice in the following proceeding before the
`
`Novo Nordisk A/S Ex. 2001, P. 2
`Fresenius Kabi v. Novo Nordisk
`IPR2022-00657
`
`
`
`Office: Mylan Institutional LLC v. Novo Nordisk A/S, IPR2020-00324 (Paper No.
`
`12).
`
`8. I am familiar with the subject matter of U.S. Patent No. 8,114,833 (“the
`
`’833 patent”) at issue in this proceeding, including its prosecution history and the
`
`scientific field to which the ’833 patent relates. I have served or am currently serving
`
`as counsel for Patent Owner in the following district court litigations involving the
`
`’833 patent: Novo Nordisk Inc. and Novo Nordisk A/S v. Teva Pharmaceuticals, Inc.
`
`and Teva USA Pharmaceuticals, Inc., 1:17-cv-00227 (D. Del.), Novo Nordisk Inc.
`
`and Novo Nordisk A/S v. Mylan Institutional LLC, 19-cv-01551-CFC (D. Del.);
`
`Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan Institutional LLC, 19-cv-164
`
`(N.D. W. Va.); Novo Nordisk Inc. and Novo Nordisk A/S v. Sandoz Inc., 1:20-cv-
`
`00747 (D. Del.); Novo Nordisk Inc. and Novo Nordisk A/S v. Sandoz Inc., 1:20-cv-
`
`06842 (D.N.J.); Novo Nordisk Inc. and Novo Nordisk A/S v. Teva Pharmaceuticals,
`
`Inc. and Teva USA Pharmaceuticals, Inc., 1:21-cv-01782 (D. Del.); Novo Nordisk
`
`Inc. and Novo Nordisk A/S v. Hikma Pharmaceuticals USA Inc., 1:21-cv-01783 (D.
`
`Del.); Novo Nordisk Inc. and Novo Nordisk A/S v. Aurobindo Pharma USA, Inc., et
`
`al., 1:22-cv-00295 (D. Del.); and Novo Nordisk Inc. and Novo Nordisk A/S v. Mylan
`
`Pharmaceuticals Inc., 1:22-cv-00023 (N.D. W. Va.). Additionally, I have been
`
`involved have served as counsel for Patent Owner in the following Office proceeding
`
`involving the ’833 Patent: Mylan Institutional LLC v. Novo Nordisk A/S, IPR2020-
`
`Novo Nordisk A/S Ex. 2001, P. 3
`Fresenius Kabi v. Novo Nordisk
`IPR2022-00657
`
`
`
`00324. Over the course of these proceedings, I have developed a thorough
`
`understanding of the ’833 patent, the relevant art, and the scientific field.
`
`9. I am an experienced litigating attorney with over ten years in private
`
`practice. During this time, I have gained experience representing clients in patent
`
`infringement matters at trial, summary judgment hearings, and in Markman
`
`hearings. I have been counsel in over 30 patent infringement cases, most of which
`
`have involved pharmaceutical patents, and have represented clients in at least four
`
`United States District Courts and at the United States Court of Appeals for the
`
`Federal Circuit. I additionally have extensive experience advising clients on the
`
`validity and infringement of pharmaceutical patents, working with experts, and
`
`developing strategies related to enforcement of pharmaceutical patents.
`
`10. I hereby declare that all statements made herein of my own knowledge
`
`are true and that all statements made on information and belief are believed to be
`
`true; and further that all statements herein are made with knowledge that willful false
`
`statements and the like are punishable by fine or imprisonment, or both, under
`
`Section 1001 of Title 18 of the United States Code.
`
`Novo Nordisk A/S Ex. 2001, P. 4
`Fresenius Kabi v. Novo Nordisk
`IPR2022-00657
`
`
`
`Dated: June 13, 2022
`
`Respectfully submitted,
`
`/Laura T. Moran/
`Laura T. Moran
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`laura.moran@fenwick.com
`
`Novo Nordisk A/S Ex. 2001, P. 5
`Fresenius Kabi v. Novo Nordisk
`IPR2022-00657
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
